MobbleOpen in Mobble ⇢
Business · Stock markets · published 2026-10-11 · via StockTitan

BridgeBio's Encaleret Shows Symptom and Bone Turnover Benefits in Phase 3 ADH1 Trial

Image via StockTitan
Image via StockTitan

BridgeBio presented Phase 3 CALIBRATE data showing encaleret improved patient-reported symptoms and raised bone turnover in ADH1. Every encaleret participant reported improvement in at least one symptom, versus 46% on standard care, and 91% reached at least the lower normal limit for parathyroid hormone at 24 weeks compared with 0%. The FDA accepted the ADH1 application for Priority Review with a May 8, 2027 target action date, a European application was submitted, and the first participant received encaleret in the Phase 3 RECLAIM-HP study for chronic hypoparathyroidism.

Expanded Detail

EXPANDED:

BridgeBio's Phase 3 CALIBRATE data

Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Read the full article at StockTitan →
Related stories
Merck Reports One-Year BRUNELLO Data for Remigromig in Diabetic Macular Edema · Stock markets
First Tracks to Report Phase 1b Celiac Data for ANB033 on Oct. 12 · Stock markets
Real-World Study Links Acoramidis to Better Outcomes Than Tafamidis in ATTR-CM · Stock markets
Genentech Shares One-Year Phase III Results for Vamikibart in Uveitic Macular Edema · Stock markets
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 | BBIO Stock News.” Browse more stories.